HESI B
Rho (D) Immune
Globulin Administration
Review Exam 88%
Q&A
2024
, 1. A nurse is preparing to administer Rho (D) immune globulin to a client
who is Rh-negative and has delivered an Rh-positive newborn. The nurse
should explain to the client that the purpose of this medication is to:
a) prevent hemolytic disease of the newborn in future pregnancies.
b) increase the production of maternal antibodies against Rh factor.
c) decrease the risk of Rh sensitization in the newborn.
d) enhance the clearance of fetal blood cells from the maternal circulation.
Answer: A. Rationale: Rho (D) immune globulin prevents the maternal
immune system from developing antibodies against Rh factor, which can
cause hemolytic disease of the newborn in subsequent pregnancies. It does
not affect the production of maternal antibodies, the risk of Rh
sensitization in the newborn, or the clearance of fetal blood cells.
2. A nurse is reviewing the laboratory results of a client who received Rho
(D) immune globulin during her pregnancy. The nurse should identify that
which of the following findings indicates a positive response to the
medication?
a) negative direct Coombs' test
b) negative indirect Coombs' test
c) positive direct Coombs' test
d) positive indirect Coombs' test
Answer: B. Rationale: A negative indirect Coombs' test indicates that the
client does not have antibodies against Rh factor in her serum, which
means that she has not been sensitized by the exposure to fetal blood cells.
A positive indirect Coombs' test indicates that the client has antibodies
against Rh factor, which can cause hemolytic disease of the newborn in
future pregnancies. A direct Coombs' test detects antibodies on the surface
of red blood cells, which is not relevant to the effectiveness of Rho (D)
immune globulin.
3. A nurse is caring for a client who is 28 weeks of gestation and is
scheduled to receive Rho (D) immune globulin. The nurse should instruct
the client to avoid receiving which of the following vaccines for at least 3
months after the administration of Rho (D) immune globulin?
a) influenza
b) tetanus
Rho (D) Immune
Globulin Administration
Review Exam 88%
Q&A
2024
, 1. A nurse is preparing to administer Rho (D) immune globulin to a client
who is Rh-negative and has delivered an Rh-positive newborn. The nurse
should explain to the client that the purpose of this medication is to:
a) prevent hemolytic disease of the newborn in future pregnancies.
b) increase the production of maternal antibodies against Rh factor.
c) decrease the risk of Rh sensitization in the newborn.
d) enhance the clearance of fetal blood cells from the maternal circulation.
Answer: A. Rationale: Rho (D) immune globulin prevents the maternal
immune system from developing antibodies against Rh factor, which can
cause hemolytic disease of the newborn in subsequent pregnancies. It does
not affect the production of maternal antibodies, the risk of Rh
sensitization in the newborn, or the clearance of fetal blood cells.
2. A nurse is reviewing the laboratory results of a client who received Rho
(D) immune globulin during her pregnancy. The nurse should identify that
which of the following findings indicates a positive response to the
medication?
a) negative direct Coombs' test
b) negative indirect Coombs' test
c) positive direct Coombs' test
d) positive indirect Coombs' test
Answer: B. Rationale: A negative indirect Coombs' test indicates that the
client does not have antibodies against Rh factor in her serum, which
means that she has not been sensitized by the exposure to fetal blood cells.
A positive indirect Coombs' test indicates that the client has antibodies
against Rh factor, which can cause hemolytic disease of the newborn in
future pregnancies. A direct Coombs' test detects antibodies on the surface
of red blood cells, which is not relevant to the effectiveness of Rho (D)
immune globulin.
3. A nurse is caring for a client who is 28 weeks of gestation and is
scheduled to receive Rho (D) immune globulin. The nurse should instruct
the client to avoid receiving which of the following vaccines for at least 3
months after the administration of Rho (D) immune globulin?
a) influenza
b) tetanus
